STOCK TITAN

SiNtx Technologies (SINT) Stock News

SINT NASDAQ

SINTX Technologies, Inc. develops and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. Company news centers on its advanced ceramics platform, FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, OsseoSculpt™ biologic, and SiNERGY™ silicon nitride/PEEK composite materials for patient-specific implant applications.

Recurring updates also cover commercialization milestones, first-in-human use of SINTX implants, strategic supply and private-label agreements, patent activity in antipathogenic materials, capital actions, operating efficiencies, and management or board changes. The company’s updates frame its current focus around medical-device applications, orthopedic and spine markets, U.S.-based manufacturing, and partnerships that extend the use of silicon nitride biomaterials.

Rhea-AI Summary

SINTX Technologies (NASDAQ: SINT) completed its 3D printing facility buildout as it advances its SiNERGY platform toward patient-specific orthopedic implant commercialization. The company received medical-grade additive manufacturing systems and expects its proprietary silicon nitride–PEEK composite filament from Evonik before year-end 2026.

SINTX is pursuing FDA 510(k) clearance for a defined range of patient-specific extremity implant designs and is evaluating limited opportunities for qualifying custom devices in the first quarter of 2027. Broader distribution requires regulatory clearances and manufacturing validation. The company anticipates expansion into craniomaxillofacial, or skull and facial, and spinal applications later in 2027, subject to regulatory review and other factors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
none
-
Rhea-AI Summary

SINTX Technologies (NASDAQ: SINT) reported third-quarter revenue of approximately $2.2 million as it advanced commercialization of its medical devices. Revenue compared with $208,000 a year earlier. Gross margin rose to approximately 62% from 45%, while operating loss narrowed 51% to approximately $1.6 million. Net loss narrowed to $1.595 million from $3.539 million.

Cash totaled $2.005 million at September 30, versus $4.140 million at December 31, 2025. Subsequent exercises of 941,423 Class B warrants at $2.14 per share raised approximately $2.0 million in gross proceeds. SINTX regained compliance with Nasdaq’s $2.5 million minimum stockholders’ equity requirement. It completed the limited-use release of its FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System, with initial commercial sales underway, and initiated large-animal studies of silicon nitride-treated medical textiles.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.70%
Tags
none
-
Rhea-AI Summary

SINTX Technologies (SINT) will release its third quarter 2026 financial results after market close on November 5, 2026. A conference call and webcast will follow that day at 4:30 p.m. ET to review quarterly performance. CEO and Chairman Eric Olson and CFO Kevin Trask will participate. A webcast replay will be available afterward on the company’s investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.75%
Tags
earnings date
Rhea-AI Summary

SINTX Technologies (NASDAQ: SINT) announced preliminary third-quarter revenue of $2.2 million, exceeding the high end of its previous guidance. Revenue for the quarter ended September 30, 2026 surpassed guidance of $0.9 million to $1.1 million, grew roughly 380% from Q2 and exceeded ten times the prior-year quarter. Aerospace subsidiaries of Fortune 500 companies accounted for most revenue. Shipments began against more than $3.2 million in previously announced purchase orders.

SINTX expects narrower losses than previous quarters and reiterated Q4 revenue guidance. Roughly $2.1 million in product revenue exceeded the $2.0 million quarterly trigger for calling Class B warrants. SINTX intends to call warrants covering approximately 1.88 million shares; full exercise could raise up to $4.0 million, but proceeds are not assured. Revenue is unaudited and subject to adjustment; final revenue could differ materially.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
none
-
Rhea-AI Summary

SINTX Technologies (SINT) announced a company-sponsored Orthopedics This Week Masterclass titled “Silicon Nitride in Orthopedics,” now available as an educational program for industry professionals.

The online session brings together three experts in implant retrieval, biomaterials and clinical practice to examine the science, clinical experience and potential advantages of medical-grade silicon nitride compared with legacy implant materials such as PEEK and titanium. The Masterclass discusses surface chemistry, reported bone-cell response, antibacterial characteristics, and potential applications in composites and 3D printing. SINTX highlights its SiNERGY biocomposite platform for sutures, mesh and wound dressings, and frames the event as part of its shift toward a commercially focused medical device organization in multiple orthopedic markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
none
-
Rhea-AI Summary

SINTX Technologies (SINT) will present at the 28th Annual H.C. Wainwright Global Investment Conference from September 14–16, 2026, at the Lotte New York Palace Hotel in New York City.

Chief Investment Officer Gregg Honigblum and President Ryan Elmore will deliver a company presentation and hold one-on-one meetings with investors. The presentation is expected to cover progress in commercializing the FDA-cleared SINAPTIC® Foot & Ankle Implant System, expansion of proprietary silicon nitride technology adoption, growth in contract manufacturing activities, and strategic initiatives to broaden commercial opportunities and support long-term shareholder value.

Investors can request meetings through their H.C. Wainwright representative, email meetings@hcwco.com, or contact SINTX Investor Relations at IR@sintx.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.75%
Tags
none
Rhea-AI Summary

SINTX Technologies (NASDAQ: SINT) announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders’ equity of $2.5 million for companies listed on the Nasdaq Capital Market. Nasdaq’s decision is based on SINTX’s Form 10-Q for the quarter ended June 30, 2026, which reported stockholders’ equity of approximately $4.83 million. Nasdaq confirmed that the previously disclosed stockholders’ equity deficiency matter is now closed. Management stated that resolving this listing issue supports SINTX’s efforts to strengthen the company while it focuses on commercializing its silicon nitride technologies, expanding its distribution network, and pursuing strategic partnerships aimed at supporting future revenue growth in its medical and advanced ceramics businesses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.92%
Tags
none
-
Rhea-AI Summary

SINTX Technologies (NASDAQ: SINT) issued a mid‑year 2026 business update alongside its Q2 10‑Q, emphasizing a shift from technology development toward commercial execution. The company advanced the FDA‑cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System through a Limited Use Release and built an initial network of twelve independent foot‑and‑ankle distributors in the U.S.

SINTX reported approximately $3.2 million in new industrial ceramics purchase orders, with revenue recognition expected to begin in Q3 2026, subject to delivery and acceptance. The company currently expects total revenue of $0.9–$1.1 million in Q3 2026 and $1.0–$1.3 million in Q4 2026.

During the first half, SINTX completed construction of an advanced 3D printing facility for SiNERGY™ patient‑specific silicon nitride/PEEK implants and secured an additional 12‑month period to access roughly $745,000 remaining on a National Institutes of Health grant. It also raised about $5.0 million in gross proceeds via a private placement and At‑The‑Market sales, initiated cost‑management efforts, engaged Southern Metrics to evaluate strategic opportunities, and gained Buy‑rated equity research coverage from H.C. Wainwright & Co. and Maxim Group.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.30%
Tags
none
-
Rhea-AI Summary

SINTX Technologies (NASDAQ: SINT) will release its second quarter 2026 financial results on Tuesday, August 11, 2026, after the market close, and host a conference call and webcast at 4:30 p.m. ET to review quarterly performance.

The call will feature CEO and Chairman Eric Olson and CFO Kevin Trask. Investors can join via a live webcast on the company’s investor relations site or by telephone after advance registration. A replay will be available on the Events & Webcasts page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
earnings date
Rhea-AI Summary

SINTX Technologies (NASDAQ: SINT) has engaged Southern Metrics Consulting, led by CEO and SINTX director Chris Lyons, to establish and manage a new Strategic Opportunity Management Program aimed at identifying, evaluating, and pursuing strategic opportunities to support long-term growth and enhance stockholder value.

Working with SINTX’s executive team and Board, Southern Metrics will help assess potential commercial partnerships, licensing deals, strategic investments, joint ventures, acquisitions, divestitures, and other corporate development initiatives. SINTX views this as a key step in its evolution from an advanced biomaterials developer toward a commercial-stage medical technology company leveraging its silicon nitride platforms and FDA-cleared SINAPTIC Foot & Ankle Implant System.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none

FAQ

What is the current stock price of SiNtx Technologies (SINT)?

SiNtx Technologies (SINT) last closed at $1.35.

What is the market cap of SiNtx Technologies (SINT)?

The market cap of SiNtx Technologies (SINT) is approximately $10.2M.